Interleukin-37 attenuates aortic valve lesions by inhibiting N 6-methyladenosine-mediated interleukin-1 receptor-associated kinase M degradation
Cardiovascular Research · 2025
DOI: 10.1093/cvr/cvaf012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, 2025. Verfasst von Gaopeng Xian und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, 1838 Northern Guangzhou Ave,…. Hauptthemen laut MEDLINE: Interleukin-1 Receptor-Associated Kinases, Aortic Valve, Interleukin-1, Adenosine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Program of Guangdong Province, Frontier Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory.
Abstract (Originalsprache)
Aims
Calcific aortic valve disease (CAVD) has become an increasingly important global medical problem without effective pharmacological intervention. Accumulating evidence indicates that aortic valve calcification is driven by inflammation. Interleukin-1 receptor-associated kinase M (IRAK-M) is a well-known negative regulator of inflammation, but its role in CAVD remains unclear. Methods and results Here, we stimulated aortic valve interstitial cells (AVICs) with low-dose lipopolysaccharide (LPS) to mimic the inflammatory response in aortic valve calcification and observed the expression pattern of IRAK-M. Furthermore, we generated IRAK-M−/− mice to explore the effect of IRAK-M deficiency on the aortic valve in vivo. Additionally, overexpression and knockdown experiments were performed to verify the role of IRAK-M in AVICs. Methylated RNA immunoprecipitation-quantitative polymerase chain reaction was used to detect the N6-methyladenosine (m6A) level of IRAK-M, and recombinant interleukin (IL)-37-treated AVICs were used to determine the regulatory relationship between IL-37 and IRAK-M. We found that IRAK-M expression was upregulated in the early stages of inflammation as part of a negative feedback mechanism to modulate the immune response. However, persistent inflammation increased overall m6A levels, ultimately leading to reduced IRAK-M expression. In vivo, IRAK-M−/− mice exhibited a propensity for aortic valve thickening and calcification. Overexpression and knockdown experiments showed that IRAK-M inhibited inflammation and osteogenic responses in AVICs. In addition, IL-37 restored IRAK-M expression by inhibiting m6A-mediated IRAK-M degradation to suppress inflammation and aortic valve calcification.
Conclusion
Our findings confirm that inflammation and epigenetic modifications synergistically regulate IRAK-M expression. Moreover, IRAK-M represents a potential target for mitigating aortic valve calcification. Meanwhile, IL-37 exhibited inhibitory effects on CAVD development both in vivo and in vitro, giving us hope that CAVD can be treated with drugs rather than surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Organ Failure Research, Department of Cardiology, Nanfang Hospital, Southern Medical University, 1838 Northern Guangzhou Ave, Guangzhou 510515, China.
- Key Laboratory for Organ Failure Research, Ministry of Education of the People's Republic of China, Guangzhou 510515, China.
- Guangdong Provincial Key Laboratory of Shock and Microcirculation, Southern Medical University, Guangzhou 510515, China.
- Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou 510005, China.
- Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
- School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
ORCID-Profile: Qingchun Zeng
Förderung
- National Natural Science Foundation of China
- Science and Technology Program of Guangdong Province
- Frontier Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory
- Guangzhou Science and Technology Plan
- Youth Science and Technology Innovation Talent of Guangdong TeZhi Plan
Zitieren
APA
Xian, G., Huang, R., Hu, D., Xu, M., Chen, Y., Ren, H., Xu, D., & Zeng, Q. (2025). Interleukin-37 attenuates aortic valve lesions by inhibiting N 6-methyladenosine-mediated interleukin-1 receptor-associated kinase M degradation. Cardiovascular Research. https://doi.org/10.1093/cvr/cvaf012
Vancouver
Xian G, Huang R, Hu D, Xu M, Chen Y, Ren H, et al. Interleukin-37 attenuates aortic valve lesions by inhibiting N 6-methyladenosine-mediated interleukin-1 receptor-associated kinase M degradation. Cardiovascular Research. 2025. doi:10.1093/cvr/cvaf012
BibTeX
@article{Xian2025,
author = {Xian, Gaopeng and Huang, Rong and Hu, Dongtu and Xu, Minhui and Chen, Yangchao and Ren, Hao and Xu, Dingli and Zeng, Qingchun},
title = {Interleukin-37 attenuates aortic valve lesions by inhibiting N 6-methyladenosine-mediated interleukin-1 receptor-associated kinase M degradation},
journal = {Cardiovascular Research},
year = {2025},
doi = {10.1093/cvr/cvaf012}
}
EUVIMED